HDACs and HDAC inhibitors in cancer development and therapy
Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …
New and emerging HDAC inhibitors for cancer treatment
AC West, RW Johnstone - The Journal of clinical …, 2014 - Am Soc Clin Investig
Epigenetic enzymes are often dysregulated in human tumors through mutation, altered
expression, or inappropriate recruitment to certain loci. The identification of these enzymes …
expression, or inappropriate recruitment to certain loci. The identification of these enzymes …
[HTML][HTML] Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy
TC Yu, F Guo, Y Yu, T Sun, D Ma, J Han, Y Qian… - Cell, 2017 - cell.com
Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure
is the major cause of recurrence and poor prognosis in colorectal cancer patients. Here, we …
is the major cause of recurrence and poor prognosis in colorectal cancer patients. Here, we …
HDAC inhibitors in acute myeloid leukemia
E San José-Enériz, N Gimenez-Camino, X Agirre… - Cancers, 2019 - mdpi.com
Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …
Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy
Cancer initiation and progression are the result of genetic and/or epigenetic alterations.
Acetylation-mediated histone/non-histone protein modification plays an important role in the …
Acetylation-mediated histone/non-histone protein modification plays an important role in the …
[HTML][HTML] Histone deacetylases and cancer
B Barneda-Zahonero, M Parra - Molecular oncology, 2012 - Elsevier
Reversible acetylation of histone and non-histone proteins is one of the most abundant post-
translational modifications in eukaryotic cells. Protein acetylation and deacetylation are …
translational modifications in eukaryotic cells. Protein acetylation and deacetylation are …
HDAC family: What are the cancer relevant targets?
O Witt, HE Deubzer, T Milde, I Oehme - Cancer letters, 2009 - Elsevier
Histone deacetylases comprise a family of 18 genes, which are grouped into classes I–IV
based on their homology to their respective yeast orthologues. Classes I, II, and IV consist of …
based on their homology to their respective yeast orthologues. Classes I, II, and IV consist of …
Inhibitors of histone deacetylase as antitumor agents: A critical review
M Manal, MJN Chandrasekar, JG Priya, MJ Nanjan - Bioorganic chemistry, 2016 - Elsevier
Abstract Histone deacetylase (EC 3.5. 1.98–HDAC) is an amidohydrolase involved in
deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital …
deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital …
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator …
S Ogino, K Nosho, N Irahara, JA Meyerhardt… - Clinical Cancer …, 2009 - AACR
Purpose: Host immune response to tumor may be an important prognostic factor for colon
cancer patients. However, little is known on prognostic significance of histopathologic …
cancer patients. However, little is known on prognostic significance of histopathologic …